FDA Approves Unknown Drug — ALVOGEN

ALVOGEN announced on November 8, 2018, the approval of its Abbreviated New Drug Application (ANDA208540), signaling the company's strategic expansion into a new therapeutic niche. The regulatory clearance presents a significant market opportunity for ALVOGEN to capitalize on import demand and potentially capture revenue from a vital segment of the pharmaceutical landscape.